Leveraging Immunotherapy with Nanomedicine - DSA-IPHC Accéder directement au contenu
Article Dans Une Revue Advanced Therapeutics Année : 2020

Leveraging Immunotherapy with Nanomedicine

Résumé

Considerable progress has been made in the development and understanding of immunotherapy, notably with the emergence of novel chimeric antigen receptor T cells (CAR‐T) which changed the perception of personalized therapy. However, cell‐based immunotherapy not only lacks therapeutic efficiency in various solid cancers but also raises concerns related to important side effects. The convergence of immunotherapy and nanomedicine is timely as nanoparticles can now be easily conjugated to various antibodies and peptides enabling outstanding abilities to target specific cell populations in vivo. Here, the state of the art of immunonanotherapy that activates the immune system in vivo, by acting either as vaccines or as tumor microenvironment (TME) activators is described. Then, the development of ex vivo immune‐cell surface labeling strategies is discussed to exploit immune cells as trojan horses and thereby improving the delivery of the therapeutics in the TME. Such a strategy is likely to considerably amplify the efficacy of immunotherapy.
Fichier principal
Vignette du fichier
Review_ImmunoNano_V3 LC (002).pdf (741.38 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02965461 , version 1 (17-05-2021)

Identifiants

Citer

Vincent Mittelheisser, Mainak Banerjee, Xavier Pivot, Loïc Charbonnière, Jacky Goetz, et al.. Leveraging Immunotherapy with Nanomedicine. Advanced Therapeutics, 2020, 3 (12), pp.2000134. ⟨10.1002/adtp.202000134⟩. ⟨hal-02965461⟩
77 Consultations
55 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More